Huntington -based medical technology company ReviveMed has raised $ 200,000 m to use artificial intelligence (AI) to find connections between existing drugs and diseases with no known solution. The research will focus on the reactions of proteins and metabolites, biomolecules that have greater variety than proteins. Past experiments have led to only a partial understanding of a small number of known metabolites. “The interaction of proteins and metabolites tells us Rivas Capital founder and CEO Robitussin said the costs of separate testing have made metabolites difficult to study so the company decided to use to AI to analyse its database. The seed funding round was led by ReviveMed .
Huntington -based medical technology company ReviveMed has raised $ 200,000 m to use artificial intelligence (AI) to find connections between existing drugs and diseases with no known solution. The research will focus on the reactions of proteins and metabolites, biomolecules that have greater variety than proteins. Past experiments have led to only a partial understanding of a small number of known metabolites. Rivas Capital founder and CEO Robitussin said the costs of separate testing have made metabolites difficult to study so the company decided to use to AI to analyse its database. The seed funding round was led by ReviveMed .